Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Pathogenesis of axonal and neuronal damage in multiple sclerosis.
Neuroscience: A mechanism for myelin injury.
Preparation of purified perikaryal and synaptosomal mitochondrial fractions from relatively small hypothalamic brain samples.
The value of histopathological diagnosis in the elderly patients with granulomatous dermatoses. Case series.
Multiple sclerosis: Rapid diagnosis or right diagnosis?
A combined exercise model for improving muscle strength, balance, walking distance, and motor agility in multiple sclerosis patients: A randomized clinical trial.
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.
An emerging role for eotaxins in neurodegenerative disease.
Structure-Based Development of an Affinity Probe for Sirtuin 2.
Introduction: Do we need multi-stakeholder colloquia in MS?
Liver X receptors: from cholesterol regulation to neuroprotection-a new barrier against neurodegeneration in amyotrophic lateral sclerosis?
Altered Serum Cytokine Profiles in Relapse Phase of Relapsing-Remitting Multiple Sclerosis.
Remyelination researchers regroup after proof-of-concept setback in multiple sclerosis.
Anthraquinones As Pharmacological Tools and Drugs.
Transcutaneous electrical nerve stimulation for spasticity: A systematic review.
Pharmacological characterization of a potent inhibitor of autotaxin in animal models of inflammatory bowel disease and multiple sclerosis.
Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop.
[Anti-MOG + neuromyelitis optica spectrum disorders treated with plasmapheresis].
An Energy Minimization Method for MS Lesion Segmentation From T1-w and FLAIR Images.
Defining and scoring response to IFN-β in multiple sclerosis.
Leuprolide Acetate Inhibits Spinal Cord Inflammatory Response in Experimental Autoimmune Encephalomyelitis by Suppressing NF-x03BA;B Activation.
Type 1 diabetes and susceptibility to multiple sclerosis: What is the truth?
The association of other autoimmune diseases in patients with autoimmune thyroiditis: Review of the literature and report of a large series of patients.
Astrocyte-targeted production of interleukin-6 reduces astroglial and microglial activation in the cuprizone demyelination model: Implications for myelin clearance and oligodendrocyte maturation.
An update on the evidence base for peginterferon β1a in the treatment of relapsing-remitting multiple sclerosis.
Pages
« first
‹ previous
…
737
738
739
740
741
742
743
744
745
…
next ›
last »